Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EP1615Y] to Cytokeratin 16/K16
- Suitable for: WB
- Reacts with: Human
- Conjugation: HRP
Product nameHRP Anti-Cytokeratin 16/K16 antibody [EP1615Y]
See all Cytokeratin 16/K16 primary antibodies
DescriptionHRP Rabbit monoclonal [EP1615Y] to Cytokeratin 16/K16
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic peptide within Human Cytokeratin 16/K16 aa 1-100 (N terminal). The exact sequence is proprietary.
Database link: P08779
- WB: HaCaT whole cell lysate.
Previously labelled as Cytokeratin 16.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
- Alexa Fluor® 488 Anti-Cytokeratin 16/K16 antibody [EP1615Y] (ab205744)
- Alexa Fluor® 647 Anti-Cytokeratin 16/K16 antibody [EP1615Y] (ab205745)
- Alexa Fluor® 555 Anti-Cytokeratin 16/K16 antibody [EP1615Y] (ab215292)
- Anti-Cytokeratin 16/K16 antibody [EP1615Y] - BSA and Azide free (ab232522)
- Anti-Cytokeratin 16/K16 antibody [EP1615Y] (ab76416)
Our Abpromise guarantee covers the use of ab206064 in the following tested applications.
|WB||1/5000. Detects a band of approximately 51 kDa (predicted molecular weight: 51 kDa).|
Tissue specificityExpressed in the hair follicle, nail bed and in mucosal stratified squamous epithelia and, suprabasally, in oral epithelium and palmoplantar epidermis. Also found in luminal cells of sweat and mammary gland ducts.
Involvement in diseaseDefects in KRT16 are a cause of pachyonychia congenita type 1 (PC1) [MIM:167200]; also known as Jadassohn-Lewandowsky syndrome. PC1 is an autosomal dominant ectodermal dysplasia characterized by hypertrophic nail dystrophy resulting in onchyogryposis (thickening and increase in curvature of the nail), palmoplantar keratoderma, follicular hyperkeratosis, and oral leukokeratosis. Hyperhidrosis of the hands and feet is usually present.
Defects in KRT16 are the cause of palmoplantar keratoderma non-epidermolytic focal (FNEPPK) [MIM:613000]. A dermatological disorder characterized by non-epidermolytic palmoplantar keratoderma limited to the pressure points on the balls of the feet, with later mild involvement on the palms. Oral, genital and follicular keratotic lesions are often present.
Defects in KRT16 are a cause of unilateral palmoplantar verrucous nevus (UPVN) [MIM:144200]. UPVN is characterized by a localized thickening of the skin in parts of the right palm and the right sole.
Note=KRT16 and KRT17 are coexpressed only in pathological situations such as metaplasias and carcinomas of the uterine cervix and in psoriasis vulgaris.
Sequence similaritiesBelongs to the intermediate filament family.
- Information by UniProt
- CK 16 antibody
- CK-16 antibody
- CK16 antibody
HRP Anti-Cytokeratin 16/K16 antibody [EP1615Y] (ab206064) at 1/5000 dilution + HaCaT (Human keratinocyte cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 51 kDa
Observed band size: 51 kDa
Exposure time: 16 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab206064 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab206064 has not yet been referenced specifically in any publications.